Florida, USA-based Accentia Biopharmaceuticals has entered into definitive agreements for a private placement offering of convertible preferred stock and warrants to new and existing institutional investors for gross proceeds of around $8.7 million before fees and expenses. Rodman & Renshaw acted as the exclusive placement agent.
Accentia intends to use the proceeds as working capital, including supporting drug development, regulatory strategies and marketing plans. Chief executive Frank O'Donnell, elaborated: "we believe we are on the verge of achieving a series of very important milestones, including reporting the unblinded results from our pivotal Phase III clinical trial of SinuNase [a novel application and formulation of a known sinusitis treatment] in March. In order to be best positioned to take advantage of anticipated positive results, there are time-sensitive priorities that, if started immediately, should accelerate our commercialization strategies. We expect that this funding will support such activities for SinuNase including preparations for a potential New Drug Application, commencing an eight-week clinical study of a pump spray formulation for mild-to-moderate sinusitis and organizing a confirmatory Phase III study for the lavage formulation."
SinuNase targets the treatment of chronic sinusitis, a debilitating disease that affects more than 60 million sufferers in the USA and Europe, the company noted.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze